



(51) International Patent Classification:

C07D 215/44 (2006.01) **C07D 413/14** (2006.01)
C07D 401/04 (2006.01) **C07D 417/14** (2006.01)
C07D 401/12 (2006.01) **C07D 471/04** (2006.01)
C07D 401/14 (2006.01) **A61K 31/4706** (2006.01)
C07D 407/14 (2006.01) **A61K 31/4709** (2006.01)
C07D 409/12 (2006.01) **A61P 29/00** (2006.01)

(21) International Application Number:

PCT/US2010/040027

(22) International Filing Date:

25 June 2010 (25.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/220,259 25 June 2009 (25.06.2009) US

(71) Applicant (for all designated States except US): **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).(72) Inventors: **CUSHING, Timothy D.**; 1064 Glacier Avenue, Pacifica, California 94044 (US). **DRANSFIELD, Paul John**; 630 Paris Street, San Francisco, California 94112 (US). **GONZALEZ LOPEZ DE TURISO, Felix**; 10 De Sabla Road #509, San Mateo, California 94402 (US). **JOHNSON, Michael G.**; 409 Clipper Street, San Francisco, California 94114 (US). **KOHN, Todd J.**; 818 North Delaware Street #412, San Mateo, California 94401 (US). **PATTAROPONG, Vatee**; 1426 Floribunda Avenue #1, Burlingame, California 94010 (US). **SIMARD, Jillian L.**; 2584 Bush Street, San Francisco, California 94115 (US).(74) Agent: **PERSON, Richard V.**; AMGEN INC., M/S 28-2-C, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HETEROCYCLIC COMPOUNDS AND THEIR USES

(57) **Abstract:** Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

